Canada Markets closed

Aridis Pharmaceuticals Surges as Antibody Cocktail Works Against Omicron

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Sam Boughedda

Investing.com — Aridis Pharmaceuticals Inc (NASDAQ:ARDS) shares have rallied Tuesday morning. The rise is a result of news that the company's antibody cocktail AR-701 is effective against Omicron and other Covid-19 variants.

Aridis shares doubled premarket, a positive boost for a company that's seen its stock decline throughout 2021. They are currently trading 34% above Monday's close.

The company explained that AR-703 binds to the Omicron variant "with no loss in affinity" compared with the original Covid-19 strain. Furthermore, Aridis studies showed that AR-701 had neutralization against all of the variants tested.

"Omicron has rendered current COVID-19 vaccines and monoclonal antibodies substantially less effective, and likely future COVID 19 variants will arise that continue this trend," said Vu Truong, CEO of Aridis Pharmaceuticals.

Adding: "Our laboratory data suggest that AR-701 has the potential to be a future-proof COVID-19 therapy that can protect against SARS-CoV-2, SARS, or MERS pandemics."

Related Articles

Aridis Pharmaceuticals Surges as Antibody Cocktail Works Against Omicron

Texas lawsuit by laundromat owners seeks to block Shell refinery sale to Pemex

Global stocks buoyed by renewed risk appetite; oil rebounds

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting